Endogenous CD4


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
06 2019
Historique:
received: 15 06 2018
revised: 12 11 2018
accepted: 24 04 2019
pubmed: 3 5 2019
medline: 6 8 2020
entrez: 3 5 2019
Statut: ppublish

Résumé

T cells specific for neoantigens encoded by mutated genes in cancers are increasingly recognized as mediators of tumor destruction after immune-checkpoint inhibitor therapy or adoptive cell transfer. Much of the focus has been on identifying epitopes presented to CD8

Identifiants

pubmed: 31043415
pii: 2326-6066.CIR-18-0402
doi: 10.1158/2326-6066.CIR-18-0402
pmc: PMC6584616
mid: NIHMS1528384
doi:

Substances chimiques

Antigens, Neoplasm 0
KRAS protein, human 0
RNA, Messenger 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

910-922

Subventions

Organisme : NCI NIH HHS
ID : K12 CA076930
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA228944
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA114536
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009515
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

J Immunol. 2002 Jul 1;169(1):350-8
pubmed: 12077264
Cancer Sci. 2003 Nov;94(11):1003-9
pubmed: 14611679
Br J Cancer. 2006 Jan 30;94(2):275-80
pubmed: 16421594
J Immunol Methods. 1990 Apr 17;128(2):189-201
pubmed: 1691237
Blood. 2007 Mar 15;109(6):2331-8
pubmed: 17082316
Hum Immunol. 2007 Sep;68(9):779-88
pubmed: 17869653
J Immunol. 2008 Jan 1;180(1):309-18
pubmed: 18097032
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
Hum Gene Ther. 2009 Jun;20(6):630-40
pubmed: 19265475
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cancer Res. 2009 Dec 1;69(23):9003-11
pubmed: 19903853
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Lancet Oncol. 2011 Feb;12(2):175-80
pubmed: 21277552
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Clin Cancer Res. 2012 Sep 15;18(18):4910-8
pubmed: 22761469
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Immunogenetics. 2013 Oct;65(10):711-24
pubmed: 23900783
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Clin Cancer Res. 2014 Jul 1;20(13):3401-10
pubmed: 24987109
Curr Protoc Bioinformatics. 2013;43:11.10.1-33
pubmed: 25431634
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Hum Mutat. 2015 Apr;36(4):E2423-9
pubmed: 25703262
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
RNA Biol. 2016 Sep;13(9):743-7
pubmed: 27031749
Curr Protoc Hum Genet. 2016 Oct 11;91:10.11.1-10.11.37
pubmed: 27727438
Clin Cancer Res. 2017 May 1;23(9):2255-2266
pubmed: 27815355
Cancer Discov. 2017 Mar;7(3):264-276
pubmed: 28031159
Cell. 2017 Jan 26;168(3):487-502.e15
pubmed: 28111070
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
Nature. 2017 May 25;545(7655):452-456
pubmed: 28514453
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Cell. 2017 Nov 30;171(6):1272-1283.e15
pubmed: 29107334
Nat Commun. 2017 Nov 23;8(1):1738
pubmed: 29170503
J Clin Invest. 2018 Apr 2;128(4):1563-1568
pubmed: 29360643
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282837
Cell. 2018 Dec 13;175(7):1991
pubmed: 30550793
Nat Commun. 2019 Jan 25;10(1):449
pubmed: 30683863

Auteurs

Joshua R Veatch (JR)

Immunotherapy Integrated Research Center, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. jveatch@fhcrc.org.

Brenda L Jesernig (BL)

Immunotherapy Integrated Research Center, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Julia Kargl (J)

Immunotherapy Integrated Research Center, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Otto Loewi Research Center, Pharmacology, Medical University of Graz, Graz, Austria.

Matthew Fitzgibbon (M)

Immunotherapy Integrated Research Center, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Sylvia M Lee (SM)

Division of Medical Oncology, University of Washington, Seattle, Washington.

Christina Baik (C)

Division of Medical Oncology, University of Washington, Seattle, Washington.

Renato Martins (R)

Division of Medical Oncology, University of Washington, Seattle, Washington.

A McGarry Houghton (AM)

Immunotherapy Integrated Research Center, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Stanley R Riddell (SR)

Immunotherapy Integrated Research Center, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH